RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Response…
Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽🤝🧑🏽 n=47 🙌 Response rate 48% 🤩 Responses seen in 10/12 pts w/ either NF2 or FH mutations #JCO #kcsm @chunghanlee3 https://t.co/gOiw3fYUrH https://t.co/OsQYFdDtJ8
RT @Amolpatel_dr: I have started loving this combination. Cabozantinib plus Nivolumab. @Priya1111 @Prasshmehta @batraatulmd @drdgoldstein…
Cabozantinib más nivolumab muestran eficacia en muchas variantes del cáncer de células renales no claras, particularmente los que tienen rasgos papilares #events #safety #cabozantinib #nivolumab #renal #cancer https://t.co/neNtxmFGXK
I have started loving this combination. Cabozantinib plus Nivolumab. @Priya1111 @Prasshmehta @batraatulmd @drdgoldstein We have generic Cabo available and also Nivo mg/kg or flat dose.
In single-arm phase II study of cabozantinib + nivo in non-clear-cell RCC, ORR was 47.5%, mPFS 12.5 mo and mOS 28 mo in papillary, unclassified or translocation-associated RCC, with no responses in chromophobe RCC. The incidence of grade 3–4 TRAEs was 32%
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @sogug1: Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates | Jou…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates | Journal of Clinical Oncology https://t.co/95N0fkRp6g
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot…
Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @motzermd @MSKCancerCenter https://t.co/pmYxGoA3eH